UK scientists are developing a vaccine for the Bundibugyo strain of Ebola, with trials potentially ready within months, as an outbreak in the Democratic Republic of Congo (DRC) has been described by the World Health Organization (WHO) Director-General as "spreading rapidly."
The Bundibugyo strain is a rare species of Ebola that kills approximately one-third of those infected, according to BBC reporting. Currently, there is no proven vaccine available for this particular strain, representing a gap in available medical countermeasures for this pathogen.
The Oxford Vaccine Group is leading the development of the new vaccine. According to the Telegraph, the vaccine utilizes the same technology that was employed in the AstraZeneca Covid-19 vaccine. This approach applies an established vaccine platform technology to address the Bundibugyo strain specifically.
The WHO Director-General's characterization of the outbreak as "spreading rapidly" underscores the ongoing public health situation in the DRC. This assessment from the international health organization highlights the active nature of virus transmission in the affected region.
Scientists working on the vaccine development have indicated that the candidate could be ready for trials within months. This timeline reflects the current projection for advancing the vaccine into clinical testing phases.
The Bundibugyo Ebola strain, while classified as a rare species, presents significant health risks due to its mortality rate of approximately one-third of those infected. The absence of a proven vaccine for this strain has been noted as a concern in outbreak response capabilities.
The Oxford Vaccine Group's work builds upon their previous vaccine development experience. The technology platform that supported the AstraZeneca Covid-19 vaccine is being adapted to target the Bundibugyo strain, representing an application of existing scientific infrastructure to a new pathogen.
The current Ebola outbreak in the DRC remains under observation by international health authorities. The WHO's assessment of the outbreak's progression informs the broader context in which vaccine development efforts are proceeding.
Read the original coverage
💬 Comments
📜 Comment Policy